Damora Therapeutics, Inc
Price
FilingsNewest: 10-Q, Quarterly reportAug 10 →InsidersNo open-market buys. 3 insiders sold $23,308, 0 of 3 sales on a 10b5-1 plan.→Financing →PeersClosest companies: JBIO, SYRE, RLAY→
From the filings
Figures
- Net income
- −$262.8Mlast 12 months
- Operating cash flow
- −$24.9Mlast 12 months
- Cash and equivalents
- $540.5Mat the last balance sheet
- Shares outstanding
- 61.7M shareson issue